Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.